SNPX - Synaptogenix: High-Risk High-Reward For Potential Alzheimer's Disease Treatment
- SNPX did not achieve primary endpoints in two Phase 2 studies for Bryostatin for the treatment of Alzheimer’s Disease in moderately severe to severe patients.
- Post-hoc analysis of 95 patients from these two studies with MMSE 10-15, and not taking Namenda, revealed a statistically significant improvement vs placebo.
- Based on learnings from the first two trials, a third trial is underway with a longer duration (6 vs 3 months) and a narrowed patient population – read-out targeted for 2H2022.
- The probability of success in the current trial is reasonable based on the learnings from the first two trials, but the small size is a risk that a statistically-significant improvement may not be achieved.
- The potential large upside affords a highly positive asymmetric risk-reward.
For further details see:
Synaptogenix: High-Risk High-Reward For Potential Alzheimer's Disease Treatment